Emosis Diagnostics SAS articles

Immunoassays for heparin dependent antibodies have been introduced since the discovery of PF4 as the major target antigen in presence of heparin. Different immunoassay presentations are available, and interestingly heparin can   be   replaced   by   polyanions complexes and its native structure is then altered as shown on figure 3.

This alteration exposes PF4 epitopes, characteristic of the molecule involvement in heparin complexes, which can bi

Many of the heparin dependent antibodies, including those with the IgG isotype, are asymptomatic, and only a subgroup of antibodies is positive in platelet activation assays. What differentiates pathogenic from asymptomatic antibodies is not fully understood, with the exception that there is some relationship between antibody concentration and occurrence of HIT, and that antibodies with the highest affinity to HPF4 are those with the strongest capacity to activate platelets. Probably, the imm

Today, HIT remains a critical clinical context in many hospital settings, when heparin, mainly unfractionated, is used in cardiology, intensive care units, or ECC, including CPB and increasingly ECMO. This is a paradoxal disease, as this anticoagulant drug can provoke thrombocytopenia associated with thrombosis in affected patients. Detecting the risk of HIT is mandatory, as it requires an immediate heparin withdrawal, and to switch to another anticoagulant therapy. However, if ruled out, hep